Hematology

Latest News

Elevating Value in Cancer Care With Innovations, Accessibility, Equity
Elevating Value in Cancer Care With Innovations, Accessibility, Equity

November 21st 2024

Coverage from the IVBM Regional event in Denver, Colorado.

AML cells concept | image credit: sovova - stock.adobe.com
Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

November 21st 2024

Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

November 19th 2024

Don M. Benson, MD, PhD, James Cancer Hospital
Elevating Myeloma Care Amidst Complex Treatment Choices

November 15th 2024

Genes - CrazyJuke - stock.adobe.com
NUP98 Rearrangements Linked to Poor Outcomes in AML

November 15th 2024

More News

Red blood cells
September 3rd 2020

Combination Therapy Benefits High-Risk Patients With MM, Study Says

Jared Kaltwasser
A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy.
plasma cells
August 31st 2020

Plasma Exchange Therapy MM Use, Cost Rose During Past 25 Years

Jared Kaltwasser
A new analysis finds therapeutic plasma exchange has become more costly, and more common among patients with multiple myeloma.
Picture of red blood cells
August 26th 2020

MRD an Exciting Advance, but Not Ready for MM Care Yet, Review Says

Jared Kaltwasser
A new opinion article suggests minimal residual disease (MRD) is not yet ready for “prime time” in the clinic, even though it’s already making a major impact on clinical trials.
MWN logo
August 17th 2020

FDA Actions Include Third CAR T-cell Therapy

AJMC Staff
Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.
Review: MM Outcomes Greatly Improving, but New Agents Still Needed
August 16th 2020

Review: MM Outcomes Greatly Improving, but New Agents Still Needed

Jared Kaltwasser
Investigators have made tremendous strides improving patient care in multiple myeloma (MM), but the authors of a new review article say much more work is needed.
MRD, Biomarkers in Multiple Myeloma
August 15th 2020

MRD, Biomarkers in Multiple Myeloma

AJMC Staff
Clinical updates for August 2020 featured in Evidence-Based Oncology.
MRD? We’re Aware of It, Say Oncologists, But We Don’t Use It for Decisions
August 14th 2020

MRD? We’re Aware of It, Say Oncologists, But We Don’t Use It for Decisions

Jared Kaltwasser
Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma.
COVID-19
August 10th 2020

Study Details Which Patients With MM, COVID-19 May Have Worse Prognosis

Jared Kaltwasser
A small study out of Sweden adds to context to the puzzle of how best to treat patients with multiple myeloma who contract COVID-19.
sickle cells
August 7th 2020

Reorganization of Sickle Cell Care Leads to Dramatic Drop in Hospitalizations

Jared Kaltwasser
Yale New Haven Hospital’s reorganization of its sickle cell disease program led patients to report feeling better off and needing fewer hospitalizations. However, the change left some with the disease still feeling unsatisfied.
Analysis Finds White, African American Patients Have Similar Access to Optimal MM Treatments
August 1st 2020

Analysis Finds White, African American Patients Have Similar Access to Optimal MM Treatments

Jared Kaltwasser
New research suggests white and African American patients have similar rates of access to new treatments for multiple myeloma.
Severe Renal Impairment Worsens Outcomes in Multiple Myeloma
August 1st 2020

Severe Renal Impairment Worsens Outcomes in Multiple Myeloma

Jared Kaltwasser
A new study finds even if renal function is restored, patients who have severe renal impairment when diagnosed with multiple myeloma have lower overall survival rates.
Bristol Myers Squibb, bluebird bio Submit Second BLA for MM CAR T-Cell Treatment
July 30th 2020

Bristol Myers Squibb, bluebird bio Submit Second BLA for MM CAR T-Cell Treatment

Gianna Melillo
Bristol Myers Squibb and bluebird bio submitted a second Biologics License Application (BLA) to the FDA for idecabtagene vicleucel (ide-cel), the companies’ investigational B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell immunotherapy, indicated for adults with relapsed and refractory multiple myeloma (MM).
AJMC® in the Press, July 24, 2020
July 24th 2020

AJMC® in the Press, July 24, 2020

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Persistent Immunoparesis Reduces OS Post Allo-SCT in Patients With MM
July 24th 2020

Persistent Immunoparesis Reduces OS Post Allo-SCT in Patients With MM

Jared Kaltwasser
A new study may have uncovered reasons why some patients with multiple myeloma have poor outcomes following allogeneic stem cell transplantation.
Cannabis May Be Safe, Potentially Effective Option for Pain for Sickle Cell Disease
July 23rd 2020

Cannabis May Be Safe, Potentially Effective Option for Pain for Sickle Cell Disease

Jaime Rosenberg
According to the study, vaporized cannabis, when compared with placebo, could be a safe and potentially effective way to address pain linked with sickle cell disease. While the decreases in pain were not statistically significant, the drug did significantly decrease pain interference in mood over a 5-day inpatient stay.
Site Logo
July 22nd 2020

Janssen's Wildgust Breaks Down Bispecific Antibodies in Development for Non-Small Cell Lung Cancer and Multiple Myeloma

Maggie L. Shaw
During ASCO, Janssen presented results from the CHRYSALIS study on amivantimab, a bispecific antibody being developed to treat non–small cell lung cancer (NSCLC). The pharma giant, along with its parent company, Johnson & Johnson (J&J), had previously received a breakthrough therapy designation in December for teclistamab, another bispecific antibody indicated for potential treatment of multiple myeloma.
Study Outlines Treatment Outcomes in First Multiple Myeloma Relapse
July 18th 2020

Study Outlines Treatment Outcomes in First Multiple Myeloma Relapse

Jared Kaltwasser
Only about one-third of patients with multiple myeloma who experience a very good partial response to therapy following first relapse, according to a new study.
Lingering Questions Limit Impact of MRD in the Clinic Despite Its Growing Prominence
July 18th 2020

Lingering Questions Limit Impact of MRD in the Clinic Despite Its Growing Prominence

Jared Kaltwasser
While minimal residual disease has become an important way to track how patients respond to therapies for multiple myeloma, the treatment implications of the metric are not yet clear, according to a review article.
New Analysis Locates 2 Biomarkers for Multiple Myeloma
July 11th 2020

New Analysis Locates 2 Biomarkers for Multiple Myeloma

Jared Kaltwasser
A new analysis of bone marrow plasma cells has helped to identify two biomarkers for multiple myeloma, which appear to play a role in the prognosis and clinical characteristics of the disease.
Gut Microbiome Could Play Key Role in Multiple Myeloma
July 10th 2020

Gut Microbiome Could Play Key Role in Multiple Myeloma

Jared Kaltwasser
Scientists do not yet have a full understanding of how multiple myeloma develops, but a new article suggests the gut microbiome is one factor that may play a role.
MM Progression, Treatment Do Not Appear to Impact COVID-19 Mortality, Study Finds
July 4th 2020

MM Progression, Treatment Do Not Appear to Impact COVID-19 Mortality, Study Finds

Jared Kaltwasser
A new study that looked at a cohort of 58 patients with multiple myeloma (MM) who contracted COVID-19 found the disease itself does not appear to be linked with higher mortality when these individuals are hospitalized.
CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain
July 2nd 2020

CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain

Jared Kaltwasser
There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles.
MRD Should Be More Widely Used in Clinical Care of MM, Report Argues
June 26th 2020

MRD Should Be More Widely Used in Clinical Care of MM, Report Argues

Jared Kaltwasser
Minimal residual disease (MRD) status has been shown to be a better indicator of the prognosis of a patient with multiple myeloma (MM) than “complete remission.” Yet, it’s still not widely used in the clinic. A new article examines the problem.
What We're Reading: Bayer Settles Cancer Claims; Census Data Show Demographic Shift; Suit Alleges Regeneron Kickbacks
June 25th 2020

What We're Reading: Bayer Settles Cancer Claims; Census Data Show Demographic Shift; Suit Alleges Regeneron Kickbacks

AJMC Staff
Bayer AG agreed to settle the majority of claims alleging its product Roundup causes blood cancer; Census Bureau data show a historic demographic shift; a federal lawsuit claims Regeneron funneled millions of dollars to a charity.
What Are the Barriers to Choosing Wisely in Hematology Care?
June 19th 2020

What Are the Barriers to Choosing Wisely in Hematology Care?

Allison Inserro
The American Society of Hematology has adopted 10 of the recommendations from Choosing Wisely to encourage more high-value care, but barriers to adoption remain.
Multiple Myeloma Treatment Priorities Vary Among Patients, Clinicians, and Caregivers
June 18th 2020

Multiple Myeloma Treatment Priorities Vary Among Patients, Clinicians, and Caregivers

Jared Kaltwasser
A new survey finds patients, caregivers, and medical professionals have somewhat different priorities when considering treatment options for multiple myeloma.
New Method Enables Smartphone-Based Diagnosis of Sickle Cell Disease
June 14th 2020

New Method Enables Smartphone-Based Diagnosis of Sickle Cell Disease

Jared Kaltwasser
Patients with sickle cell disease who do not receive treatment can die from the disease, but diagnostic resources are scarce in some parts of the world where the disease is most prevalent. A new smartphone-based method could change that.
Induction Therapy Optimal for Transplant-Eligible Patients With Multiple Myeloma
June 11th 2020

Induction Therapy Optimal for Transplant-Eligible Patients With Multiple Myeloma

Jared Kaltwasser
A new large randomized trial indicates induction therapy including lenalidomide is optimal in patients with multiple myeloma who are transplant-eligible. Maintenance with lenalidomide was preferable to observation alone following transplant.
Smoldering MM Study Suggests Deeper Links to Metabolic Syndromes
June 7th 2020

Smoldering MM Study Suggests Deeper Links to Metabolic Syndromes

Jared Kaltwasser
Patients with multiple myeloma (MM) face higher risks of certain metabolic syndromes, but new research suggests those risks exist even in patients with smoldering MM.
Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care
June 2nd 2020

Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care

Jared Kaltwasser
As investigators have learned more about how to diagnose and categorize smoldering multiple myeloma (SMM), a new review article argues there’s insufficient data to evolve beyond a close observation approach.
<12345678910
...
23>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo